Movement Alert｜Twist Bioscience Corp Falls 5.27% in Regular Trading, Neutral Broker Initiations Keep Valuation Debate Alive

Market Focus10-16 21:47

On October 16, Twist Bioscience Corp fell 5.27% in Regular Trading, trading at $137.126/share, with turnover of $20.1367 million.

The move came as the market continued to digest recent broker coverage that stopped at neutral recommendations, leaving investors without a fresh upside catalyst.

Recent coverage showed Jefferies initiating Twist Bioscience Corp at Hold with a $150 price target, while UBS earlier started coverage with a Neutral rating and a $144 target. Both target prices were broadly close to prevailing trading levels at the time, and the succession of neutral views has reinforced near-term valuation disagreement around the company’s synthetic DNA and AIDD-related business, with the stock remaining under pressure in recent sessions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment